Proteus pins hopes on gene discovery

Paul Rodgers explains why large drug firms suddenly want to talk to a small biotech company

LONG-SUFFERING investors in Proteus, a biotechnology company, may be sceptical, especially when they see its financial results on Thursday. But Jurek Sikorski, the new chief executive, is confident the company is about to turn the corner, thanks to a new technology he believes is capable of targeting the genes behind diseases ranging from rheumatoid arthritis to cancer and Aids.

Proteus, like most biotech companies, has had a turbulent life. Floated in 1990 at 84p, its shares soared to about 500p two years ago, then collapsed after UBS quit as joint broker when it failed to meet projections in the original prospectus. The stock is now languishing back at 88p, and the markets are braced for another annual loss, probably around pounds 7m, to be announced on Thursday.

But the company, based in Macclesfield, Cheshire, is now in serious talks through Progene, a joint venture with America's Genelabs Technologies, with eight international drug companies about applying its computer design techniques to formulate molecules that can block individual strings of DNA. If even a few of them sign development agreements, Proteus will have a healthy stream of revenues for the first time.

Promises of deals to come are a dime a dozen in the biotech sector, but Proteus's claim is more than just hot air. The head of cancer research at one US drugs giant called the advance the best thing he had seen in 10 years. "They came to us two years ago and, in an appropriately arrogant fashion, we kicked them out, saying that what they proposed couldn't be done. They came back 18 months later with the evidence that they'd succeeded."

Deals between other small biotechnology firms and large pharmaceutical companies typically involve a one-off cheque at the start of a development programme, and additional payments as set milestones are passed. For shareholders, the big payback will only come after a drug gets regulatory approval for use on human patients and fat royalties start to flow.

Proteus had originally aimed to sell the computer software that biochemist Dr Barry Robson began developing at the University of Manchester to pharmaceutical companies. But when they balked at the price tag, it decided to apply the system itself. Some 30 projects were spawned, fragmenting the research effort. When Mr Sikorski was brought in nine months ago, he pared the number of projects down to a dozen. Among them was Progene.

Many diseases have links to DNA, the spiralling ladder-like molecule in the nucleus of each cell that governs its biochemistry. Different sections of the molecule - the genes - are coded to represent proteins, the building blocks of life. Most of the genes are necessary for the cell's well-being but a few, such as cancer-causing oncogenes, are not. The code is written with four base-pairs, each one representing a slightly different-shaped rung on the DNA ladder.

Each gene is switched on and off by molecules called transcription factors, which bind to the DNA in front of the protein-coding sections, like grotesquely shaped men with their arms and legs wrapped through and around the rungs of a ladder. Some naturally occurring drugs also bind to these sites, blocking the transcription factors and thus the copying process.

These molecules are small, however, usually covering just four of the DNA molecule's rungs, so they have a wide choice of possible binding sites. A drug that was 12 to 16 base-pairs long is so complicated it would fit snugly only when it found the target segment. It would therefore be more effective, require a lower dose, and be less likely to cause side-effects.

Progene set about building such molecules by testing known DNA binding drugs with a patented Genelabs process called Merlin to see which combinations of base-pairs they stuck to most firmly. Each four-rung drug was tried against every possible combination of four base-pairs, 256 in all. The result was a catalogue of about 30 building blocks.

Proteus then used its custom computer software, Prometheus, to combine the building blocks into 12 base-pair molecules that match specific strings of DNA. The automated design process usually comes up with several candidates, which are then built and sent to Genelabs for further testing to ensure the new drugs do block transcription factors.

If the large drug companies sign on the dotted line, their role will be to supply Progene with DNA strings that they have linked to specific diseases. The drugs will still have to show that they can pass through the blood stream without breaking down, and that they can sneak through the cellular and nuclear membranes to reach the DNA. Finally they will have to go through tests to prove that they are safe.

Start your day with The Independent, sign up for daily news emails
Barn owls are among species that could be affected
charity appeal
Sarah Silverman (middle) with sister Reform Rabbi Susan Silverman (right) and sister actress Laura Silverman (left) at Jerusalem's Western Wall for feminist Hanuka candle-lighting ceremony
peopleControversial comedian stages pro-equality Hanukkah lighting during a protest at Jerusalem's Wailing Wall
Arts and Entertainment
The Bach Choir has been crowned the inaugural winner of Sky Arts’ show The Great Culture Quiz
arts + ents140-year-old choir declared winner of Sky Arts' 'The Great Culture Quiz'
After another poor series in Sri Lanka, Alastair Cook claimed all players go through a lean period
cricketEoin Morgan reportedly to take over ODI captaincy
ebooksA year of political gossip, levity and intrigue from the sharpest pen in Westminster
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Carlton Senior Appointments: Private Banking Manager - Intl Bank - Los Angeles

$200 - $350 per annum: Carlton Senior Appointments: Managing Producer – Office...

Carlton Senior Appointments: San Fran - Investment Advisor – Ind Advisory Firm

$125 - $225 per annum: Carlton Senior Appointments: San Fran - Investment Advi...

Sheridan Maine: Commercial Finance Manager

Up to £70,000 per annum + benefits: Sheridan Maine: Are you a qualified accoun...

Sheridan Maine: Regulatory Reporting Accountant

Up to £65,000 per annum + benefits: Sheridan Maine: Are you a qualified accoun...

Day In a Page

Homeless Veterans appeal: 'You look for someone who's an inspiration and try to be like them'

Homeless Veterans appeal

In 2010, Sgt Gary Jamieson stepped on an IED in Afghanistan and lost his legs and an arm. He reveals what, and who, helped him to make a remarkable recovery
Could cannabis oil reverse the effects of cancer?

Could cannabis oil reverse effects of cancer?

As a film following six patients receiving the controversial treatment is released, Kate Hilpern uncovers a very slippery issue
The Interview movie review: You can't see Seth Rogen and James Franco's Kim Jong Un assassination film, but you can read about it here

The Interview movie review

You can't see Seth Rogen and James Franco's Kim Jong Un assassination film, but you can read about it here
Serial mania has propelled podcasts into the cultural mainstream

How podcasts became mainstream

People have consumed gripping armchair investigation Serial with a relish typically reserved for box-set binges
Jesus Christ has become an unlikely pin-up for hipster marketing companies

Jesus Christ has become an unlikely pin-up

Kevin Lee Light, aka "Jesus", is the newest client of creative agency Mother while rival agency Anomaly has launched Sexy Jesus, depicting the Messiah in a series of Athena-style poses
Rosetta space mission voted most important scientific breakthrough of 2014

A memorable year for science – if not for mice

The most important scientific breakthroughs of 2014
Christmas cocktails to make you merry: From eggnog to Brown Betty and Rum Bumpo

Christmas cocktails to make you merry

Mulled wine is an essential seasonal treat. But now drinkers are rediscovering other traditional festive tipples. Angela Clutton raises a glass to Christmas cocktails
5 best activity trackers

Fitness technology: 5 best activity trackers

Up the ante in your regimen and change the habits of a lifetime with this wearable tech
Paul Scholes column: It's a little-known fact, but I have played one of the seven dwarves

Paul Scholes column

It's a little-known fact, but I have played one of the seven dwarves
Fifa's travelling circus once again steals limelight from real stars

Fifa's travelling circus once again steals limelight from real stars

Club World Cup kicked into the long grass by the continued farce surrounding Blatter, Garcia, Russia and Qatar
Frank Warren column: 2014 – boxing is back and winning new fans

Frank Warren: Boxing is back and winning new fans

2014 proves it's now one of sport's biggest hitters again
Jeb Bush vs Hillary Clinton: The power dynamics of the two first families

Jeb Bush vs Hillary Clinton

Karen Tumulty explores the power dynamics of the two first families
Stockholm is rivalling Silicon Valley with a hotbed of technology start-ups

Stockholm is rivalling Silicon Valley

The Swedish capital is home to two of the most popular video games in the world, as well as thousands of technology start-ups worth hundreds of millions of pounds – and it's all happened since 2009
Did Japanese workers really get their symbols mixed up and display Santa on a crucifix?

Crucified Santa: Urban myth refuses to die

The story goes that Japanese store workers created a life-size effigy of a smiling "Father Kurisumasu" attached to a facsimile of Our Lord's final instrument of torture
Jennifer Saunders and Kate Moss join David Walliams on set for TV adaptation of The Boy in the Dress

The Boy in the Dress: On set with the stars

Walliams' story about a boy who goes to school in a dress will be shown this Christmas